What the FDA labels say about taking them together
Adalimumab and cyclosporine
Adalimumab's FDA label of October 21, 2025 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name adalimumab. The adalimumab label: “Upon initiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration is recommended and the …”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation).
What does the adalimumab label say about cyclosporine?
Adalimumab label, drug interactionsUpon initiation or discontinuation of Adalimumab-adaz in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Source: FDA drug label (Humira, BLA125057), AbbVie Inc., effective December 23, 2025 (SPL set 608d4f0d-b19f-46d3-749a-7159aa5f933d), via openFDA
Source: FDA drug label (Adalimumab-Aacf, BLA761255), Fresenius Kabi USA, LLC, effective January 8, 2026 (SPL set 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915), via openFDA
Source: FDA drug label (Yusimry, BLA761216), Coherus BioSciences Inc, effective May 16, 2025 (SPL set cd0e7af2-7704-49ce-bde9-f645294b6788), via openFDA
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the cyclosporine label say about adalimumab?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name adalimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Cyclosporine | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Organ transplant rejection, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | $1.04 per unit 0.05% eye emulsion |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once